EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Early clinical efficacy of pegylated interferon treatment in patients with different phases of chronic HBV infection: A real‐world analysis

Wencong Zhang, Mingyou Xing, Wenjin Sun, Jia Chen, Nana Xie, Yuan Cai, Ying Wang, Niuniu Li, Yujin Jiang, Fan Zhang, Yanfeng Wang, Qingjin Zeng und 5 weitere

Journal of Viral Hepatitis · 2023

DOI: 10.1111/jvh.13792 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Viral Hepatitis, 2023. Verfasst von Wencong Zhang und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: Hepatitis B virus, Hepatitis B, Chronic. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although there are therapeutic advantages for hepatitis B virus (HBV) withpegylated interferon alpha (peg‐IFNα) treatment compared with nucleos(t)ide analog (NAs) therapy, the effect difference in infected population at different phases has not been well established. We studied the clinical efficacy of peg‐IFNα in two populations with HBV infection, including inactive HBsAg carrier (IHC) and chronic hepatitis B (CHB). A total of 328 HBV‐infected patients were included in this real‐world analysis. Patients were divided into two groups according to the infected stages. Peg‐IFNα monotherapy or combination therapy with NAs were used in IHCs, and peg‐IFNα added‐on NAs therapy was applied to patients with CHB. The primary efficacy endpoint was HBsAg loss at Week 24. Results: The Kaplan–Meier cumulative rates of HBsAg loss were 39.50% ( n = 47/119) in IHC group and 28.71% ( n = 60/209) in CHB group at Week 24 ( p < .05). After Propensity Score Matching (PSM), the HBsAg loss rates were 36.84% ( n = 35/95) and 32.63% ( n = 31/95), respectively ( p > .05). Patients with baseline HBsAg level < 100 IU/ml achieved higher rates of HBsAg clearance in IHC and CHB group (before PSM: 47.44% vs. 42.86%, after PSM: 49.12% vs. 45.83%, all p values > .05). Baseline HBsAg level and its level decline from baseline to Week 12 can be as the predictors for HBsAg loss at Week 24 in both groups. Hence, the efficacy of HBsAg clearance was broadly similar between IHCs and NA‐treated CHB patients during the early peg‐IFNα therapy. A significant downward trend of HBsAg level was observed in both groups during peg‐IFNα therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis B virusHepatitis B, ChronicHumansAntiviral AgentsHepatitis B Surface AntigensInterferon-alphaTreatment OutcomePolyethylene GlycolsHepatitis B e AntigensDNA, Viral

Stichwörter der Autor:innen

HBsAg losschronic hepatitis Binactive HBsAg carriernucleos(t)ide analogspegylated interferon

Substanzen

Antiviral AgentsHepatitis B Surface AntigensInterferon-alphaPolyethylene GlycolsHepatitis B e AntigensDNA, Viral

Autor:innen und Institutionen

  • Department of Infectious Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Department of Infectious Diseases, Ezhou Central Hospital, Ezhou, China.
  • Department of Liver Diseases, State Key Discipline of Infectious Disease, Shenzhen Third People's Hospital, The Second Affiliated Hospital of Southern University of Science and Technology, National Clinical Research Cen…
  • Department of Infectious Diseases, The People's Hospital of Longhua, Shenzhen, China.

Zitieren

APA

Zhang, W., Xing, M., Sun, W., Chen, J., Xie, N., Cai, Y., Wang, Y., Li, N., Jiang, Y., Zhang, F., Wang, Y., Zeng, Q., Ji, Y., Xu, C., Jiang, C., Song, J., & Li, G. (2023). Early clinical efficacy of pegylated interferon treatment in patients with different phases of chronic HBV infection: A real‐world analysis. Journal of Viral Hepatitis. https://doi.org/10.1111/jvh.13792

Vancouver

Zhang W, Xing M, Sun W, Chen J, Xie N, Cai Y, et al. Early clinical efficacy of pegylated interferon treatment in patients with different phases of chronic HBV infection: A real‐world analysis. Journal of Viral Hepatitis. 2023. doi:10.1111/jvh.13792

BibTeX
@article{Zhang2023,
  author = {Zhang, Wencong and Xing, Mingyou and Sun, Wenjin and Chen, Jia and Xie, Nana and Cai, Yuan and Wang, Ying and Li, Niuniu and Jiang, Yujin and Zhang, Fan and Wang, Yanfeng and Zeng, Qingjin and Ji, Yanhua and Xu, Cheng and Jiang, Chunmei and Song, Jianxin and Li, Guojun},
  title = {Early clinical efficacy of pegylated interferon treatment in patients with different phases of chronic HBV infection: A real‐world analysis},
  journal = {Journal of Viral Hepatitis},
  year = {2023},
  doi = {10.1111/jvh.13792}
}
Kostenlos starten →